Get the Stockscreener App
418.16
0.03%
1.98
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $418.16, with a volume of 130.72K.
It is up +0.03% in the last 24 hours and up +15.49% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$416.18
Open:
$419.92
24h Volume:
130.72K
Relative Volume:
0.05
Market Cap:
$226.25B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
29.08
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.83%
1M Performance:
+15.49%
6M Performance:
+12.76%
1Y Performance:
+43.88%
1-Day Range:
$415.82
$420.26
1-Week Range:
$401.07
$421.79
52-Week Range:
$269.77
$421.79
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
418.20 | 225.15B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,226.63 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.83 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
253.24 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
134.25 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.67 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating - marketscreener.com
Amgen stock holds near a yearly high after Q2 beats - AD HOC NEWS
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Is Amgen (AMGN) Fully Valued On Strong Q2 Results And Raised 2026 Guidance? - simplywall.st
CEO Bob Bradway’s Advice to the Next Generation of Innovators - Amgen
Does Amgen (NASDAQ:AMGN) Fit Into The Biotech and Biosimilar Story? - Kalkine Media
Amgen Stock And The Price Of A Promise - Trefis
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment - WSJ
Amgen stock trades near a yearly high after Q2 beats - AD HOC NEWS
Tema ETFs LLC Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
G&S Capital LLC Makes New $1.58 Million Investment in Amgen Inc. $AMGN - MarketBeat
AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD - PR Newswire
Amgen (AMGN) Q2 2026 Earnings Call Transcript - AOL.com
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - benzinga.com
Amgen (NASDAQ:AMGN) Hits New 1-Year HighHere's Why - MarketBeat
Handelsbanken Fonder AB Has $125.51 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by KMG Fiduciary Partners LLC - MarketBeat
Charles Schwab Trust Co Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) director Charles Holley receives stock award and reports trust holdings - Stock Titan
Amgen (AMGN) director Michael V. Drake granted 63.8764 shares in equity award - Stock Titan
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Guggenheim raises Amgen stock price target to $388 on strong quarter - Investing.com Canada
Amgen Inc. (AMGN) Stock Analysis: Navigating a Strong Market Cap with High Return on Equity - directorstalkinterviews.com
AMGEN INC : HSBC RAISES TARGET PRICE TO $445 FROM $425 - Bitget
AMGEN INC : GUGGENHEIM RAISES TARGET PRICE TO $388 FROM $343 - Bitget
Amgen Stock Jumped 8% This Week After a Guidance Raise. Here’s What’s Next - TIKR.com
Amgen Inc. (AMGN) Stock forecasts - Yahoo Finance UK
Avity Investment Management Inc. Has $27.59 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Cardano Risk Management B.V. Sells 14,358 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛
MRA Advisory Group Grows Holdings in Amgen Inc. $AMGN - MarketBeat
Teamwork Financial Advisors LLC Sells 8,835 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc (AMG) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN - MarketBeat
Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Amgen Inc. Stock 12‑Month Price Target Raised to $378.67, Implies 6% Downside - TradingView
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells 2,970 Shares of Stock - MarketBeat
Amgen: The Market Is Underestimating Its Next Growth Phase (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. $AMGN Shares Acquired by Czech National Bank - MarketBeat
Sarasin & Partners LLP Cuts Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by NewEdge Advisors LLC - MarketBeat
AMGEN INC. : WELLS FARGO RAISES TARGET PRICE TO $400 FROM $390 - webull.com
Trilogy Capital Inc. Has $302,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Jumps As Raised Guidance Meets Mounting Risks - simplywall.st
A Look at Amgen Inc (AMGN) After 4.6% Gain -- GF Value $353.96 v - GuruFocus
Amgen Stock Climbs as Drug Growth Outruns Obesity Setback - finance.yahoo.com
Amgen: First $10 Billion Quarter, More Growth Ahead (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. Stock 12‑Month Price Target Raised to $375.89, Implies 4% Downside - TradingView
Amgen Inc Stock (AMGN) Moved Up by 4.57% on Aug 5: Drivers Behind the Movement - TradingKey
AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline - The Globe and Mail
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
0.57%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):